This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Caution on Bioterror

Next week the Senate is expected to revamp Project Bioshield, a $5.6 billion spending plan meant to shore up the nation's defenses against a bioterror attack.

The original law, enacted in June 2002, was supposed to provide inducements for biotech companies to work on vaccines and antidotes for threats such as anthrax and Ebola. However, the structure of the bill actually served as a disincentive.

That's because companies weren't going to get paid until the products they developed were approved for use. Large biotechs such as Amgen (AMGN) and Genentech (DNA) had little interest in the government's program. After all, they had businesses to run.

At the same time, several smaller firms were salivating over the possibility of large contracts and eagerly signed up. The problem has been that participating companies have had a difficult time successfully developing products and getting through the period before a treatment is successfully launched, when cash is going out but none is coming in.

The newest bill, sponsored by Sen. Richard Burr (R., N.C.) will, among other things, add $1 billion to the program to fund companies prior to product approval. That should ease the financial strain for firms developing products that the government deems essential to protecting our nation's health.

Below are some of the publicly traded companies that are researching ways to protect the American public from bioterror threats. Just keep in mind that many of these companies have very low market caps, are thinly traded, have little or no revenue or track records and should be considered very speculative.
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
SIGA $0.90 -5.26%
EBS $38.30 1.19%
AAPL $92.72 -0.56%
FB $119.49 1.43%
GOOG $711.12 1.38%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs